RHOC and neoplasm: The formation of a signaling platform driven by ET-1, containing β-arr1/hMENA/hMENAΔv6/PDZ-RhoGEF and converging on the RhoC pathway, supports pericellular matrix degradation and confers also a fitness advantage to tumor cells to breach the endothelial barrier and engage them in the transendothelial migration process (Di Modugno et al., 2018).